From whatsonthorold.com
Among 7 analysts covering Anthera Pharmaceuticals (NASDAQ:ANTH), 4 have Buy rating, 1 Sell and 2 Hold. Therefore 57% are positive. Anthera Pharmaceuticals had 21 analyst reports since August 13, 2015 according to SRatingsIntel. Piper Jaffray maintained Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) rating on Thursday, December 29. Piper Jaffray has “Overweight” rating and $1.35 target. The stock has “Buy” rating by Suntrust Robinson on Wednesday, September 9. Jefferies reinitiated Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) on Friday, February 19 with “Buy” rating. The company was maintained on Monday, June 26 by Jefferies. As per Tuesday, March 6, the company rating was maintained by Jefferies. The firm has “Hold” rating by Jefferies given on Sunday, August 6. On Thursday, August 13 the stock rating was upgraded by Zacks to “Hold”. Citigroup downgraded the shares of ANTH in report on Thursday, December 29 to “Neutral” rating. The stock of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) has “Buy” rating given on Wednesday, September 9 by SunTrust. Citigroup initiated the stock with “Buy” rating in Thursday, September 17 report. See Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) latest ratings:
12/03/2018 Broker: Piper Jaffray Rating: Sell Downgrade
06/03/2018 Broker: Jefferies Rating: Hold New Target: $2.0 Maintain
21/02/2018 Broker: Roth Capital Rating: Buy New Target: $10 Initiates Coverage On
13/02/2018 Broker: Jefferies Rating: Hold New Target: $1.75 Maintain
22/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $4.0 Maintain
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. The company has market cap of $6.40 million. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of immunoglobulin A nephropathy. It currently has negative earnings.
The stock increased 6.30% or $0.0145 during the last trading session, reaching $0.2445. About 772,825 shares traded. Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) has declined 86.78% since June 10, 2017 and is downtrending. It has underperformed by 99.35% the S&P500. Some Historical ANTH News: ; 12/03/2018 – Anthera to explore options after lead drug’s trial failure; 06/03/2018 – Anthera Pharmaceuticals Deemed Compliant with Nasdaq Listing Criteria; 12/03/2018 – Anthera Pharma: Sollpura Did Achieve Secondary Endpoint of Coefficient of Nitrogen Absorption; 05/03/2018 – Anthera Pharmaceuticals 4Q Loss/Shr 73c; 12/03/2018 – Anthera Pharma: Anthera to Evaluate All Strategic Alternatives; 12/03/2018 – Anthera Pharma: Further Development of Sollpura to Be Discontinued; 05/03/2018 – Anthera Pharma: Phase 3 RESULT Study Completed Patient Dosing, Topline Data Expected March 2018; 05/03/2018 – ANTHERA PHARMACEUTICALS INC – QTRLY NET LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDERS $0.73; 12/03/2018 – Anthera Pharmaceuticals Plans to Evaluate the Full Data Outputs; 06/03/2018 – ANTHERA FILES PROSPECTUS FOR $100M MIXED SECURITIES SHELF
